Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Neti Pots, Nurse Ambassadors & American Healthcare

Philip Seo, MD, MHS  |  March 15, 2021

Just YouTube it. As a rheumatologist who sees many patients with granulomatosis with polyangiitis (GPA), I have spent a significant portion of my life talking to people about neti pots. Originally, the neti pot was part of the Ayurvedic tradition. Neti pots were used to flush the sinuses with water, milk and ghee, or to…

Filed under:OpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:medication compliancenurse ambassadors

Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks

Michele B. Kaufman, PharmD, BCGP  |  March 5, 2021

In Canada, a subcutaneous formulation of CT-P13, which is biosimilar to infliximab, was approved to treat rheumatoid arthritis.

Filed under:Biologics/DMARDsConditions Tagged with:CanadaCT-P13Drug SafetyFDAinfliximabRheumatoid Arthritis (RA)Tofacitinib

Study Explores Palindromic Rheumatism to Predict RA Development

Ruth Jessen Hickman, MD  |  March 4, 2021

Research from Ellingwood et al. examines how often patients diagnosed with early RA experience episodic joint inflammation and describes characteristics that may result in RA development.

Filed under:ConditionsRheumatoid Arthritis Tagged with:Inflammatory arthritisPalindromic RheumatismRheumatoid Arthritis (RA)

Diet, Microbes & Inflammation: Unique Microbial Genetic Strains in Inflammatory Disease, Plus a Possible Arthritis Diet

Susan Bernstein  |  March 4, 2021

Experts at ACR Convergence 2020 addressed how diet & the body’s microbiome affect chronic diseases.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020Dietgut microbiotainflammationMicrobiome

The Character of Rheumatology Has Changed Over the Past 50 Years

Bruce Rothschild, MD  |  February 16, 2021

Camelot allegedly existed once upon a time in South Wales. The name was evoked again in the 1960s, but perhaps it is also applicable to the character of rheuma­tology in the halcyon days of the 1970s and 80s.  That’s not to belittle the world we now live in, with so many treatment options for our…

Filed under:OpinionQuality Assurance/ImprovementSpeak Out Rheum Tagged with:imagingphysical examSpeak Out RheumatologyTesting

Research Outlines Benefits of bDMARDs to Treat Early RA

Michele B. Kaufman, PharmD, BCGP  |  February 10, 2021

Sapart et al. suggest a combination of methotrexate and biologic disease-modifying anti-rheumatic drugs as induction therapy for patients with early RA may lead to long-term remission.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:biologic disease-modifying antirheumatic drugsbiologic DMARDscombination therapyearly RAmonotherapyRheumatoid Arthritis (RA)

Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More

Michele B. Kaufman, PharmD, BCGP  |  February 8, 2021

In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.

Filed under:Drug Updates Tagged with:Cardiovascular diseaseHeart DiseaseriskTofacitinib

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2021

In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Ankylosing SpondylitisEuropean UnionPsoriatic Arthritisupadacitinib

Diagnostic Drill-Down: New Research Suggests Genetic Autoinflammatory Roots

Mary Beth Nierengarten  |  January 25, 2021

Two experts discussed ongoing difficulties in diagnosing autoinflammatory disease, & promising new studies that point to possible genetic roots of autoinflammatory disease.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020autoinflammatory diseaseSAPHOSAPHO Syndromesystemic autoinflammatory diseases

ilusmedical / shutterstock.com

The State of Clinical Research in Vasculitis: 2021

Shubhasree Banerjee, MD, & Peter A. Merkel, MD, MPH  |  January 19, 2021

It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…

Filed under:ConditionsResearch RheumVasculitis Tagged with:registry

  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 105
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences